Shares of Juno Therapeutics (JUNO) Rally 5.03%

Juno Therapeutics (JUNO) has been under a strong bear grip, hence the stock is down -33.99% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 3.49% in the past 1 week. The stock has risen by 5.03% in the past week indicating that the buyers are active at lower levels, but the stock is down -31.11% in the past 4 weeks. The stock has recorded a 20-day Moving Average of 22.7% and the 50-Day Moving Average is 26.62%.

Juno Therapeutics (NASDAQ:JUNO): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $28.92 and $28.55 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $29.74. The buying momentum continued till the end and the stock did not give up its gains. It closed at $29.21, notching a gain of 1.42% for the day. The total traded volume was 3,715,626 . The stock had closed at $28.80 on the previous day.


The company Insiders own 15.26% of Juno Therapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -2.39% . Institutional Investors own 58.13% of Juno Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of -4.44%. In a related news, The Securities and Exchange Commission has divulged that Klausner Richard, director of Juno Therapeutics, Inc., had unloaded 12,000 shares at an average price of $40.71 in a transaction dated on June 24, 2016. The total value of the transaction was worth $488,520.

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *